[CML] [An epidermal growth factor receptor-dependent e3B1/Abi1 protein as a tumor suppressing candidate in cancer]Rob [CML] BCR/ABL Promotes Dendritic Cell-Mediated Natural Killer Cell Activation.Rob [CML] Berbamine: A novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity.Ro...
Morita, KiyomiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USASasaki, KojiDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, USASpringer SingaporeInternational Journal of Hematology...
Molecular Cancer (2024) BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach Jenna M. Menger Ryan S. Sathianathen Nobuko Hijiya Current Oncology Reports (2024) CAR-T cells for the treatment of pediatric chronic myeloid leukemia in repeatedly relapsed lymphoid blast pha...
9,10 As such, solid tumors (eg, non–small cell lung cancer, mammary adenocarcinoma, colorectal, and gastric) and hematological cancers (B-cell lymphomas) display major histocompatibility complex (MHC) class II (MHC-II) downregulation, reducing the host immune response toward the tumor; ...
In an interview during the 2018 OncLive® State of the Science Summit™ on Hematologic Malignancies, Sweet, an assistant member in the Department of Malignant Hematology of Moffitt Cancer Center, shed light on these data regarding treatment discontinuation and how they impact patients with CML.Swe...
Lauseker M, Hanfstein B, Haferlach C, Schnittger S, Pfirrmann M, Fabarius Aet al. Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase.J Cancer Res Clin Oncol2014;140: 1965–1969. ...
Cancer immunotherapy has been found to be a powerful therapeutic modality for targeting malignant tumor cells and has revolutionized hematological malignancy therapy [6,7,8]. In CML, oncoproteins, whether BCR-ABL or BCR-ABLT315I, are necessary for tumor cell survival. CML cells cannot escape immun...
Massimino, MicheleStella, StefaniaTirro, ElenaPennisi, Maria StellaVitale, Silvia RitaPuma, AdrianaRomano, ChiaraDi Gregorio, SandraTomarchio, CristinaDi Raimondo, FrancescoManzella, LiviaUniv Catania Dept Clin &Anticancer Research: International Journal of Cancer Research and Treatment...
Non-MPN/non-cancer control groups were selected from Medicare for each MPN subtype and matched to cases 5:1 based on year of birth, gender, race, geographic location, and reason for Medicare eligibility. Survival for both case and matching controls was determined starting from the case ...
Our study was conducted on 123 elderly (鈮 75 years) CML patients across four centers in Israel and Moffitt Cancer Center, USA. The median age at diagnosis was 79.1 years, with 44.7% being octogenarians. Comorbidities were very common; cardiovascular risk factors (60%), cardiovascular diseases...